Blaze TrendsEli Lilly's $3.83 billion acquisition of Curevo, LimmaTech Biologics, and Vaccine Company signals a strategic pivot into infectious disease prevention. The buyout includes a shingles candidate positioned to challenge GSK's Shingrix. #EliLilly #Biotech #Investing #PharmaNews
https://blazetrends.com/eli-lilly-targets-gsk-and-long-term-disease-with-3-8-billion-vaccine-acquisition-spree/?fsp_sid=27829
https://blazetrends.com/eli-lilly-targets-gsk-and-long-term-disease-with-3-8-billion-vaccine-acquisition-spree/?fsp_sid=27829
Eli Lilly targets GSK and long-term disease with $3.8 billion vaccine acquisition spree
Flush with unprecedented cash from its dominant diabetes and obesity GLP-1 franchise, Eli Lilly is aggressively acquiring its way into the infectious disease sector to secure long-term revenue. The pharmaceutical company is finalizing the $3.83 billion acquisition of three clinical-stage vaccine developers: Curevo, LimmaTech Biologics, and Vaccine Company. The acquisitions, officially announced on May 26,